Surmodics (SRDX)
(Delayed Data from NSDQ)
$35.41 USD
-0.22 (-0.62%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $35.43 +0.02 (0.06%) 7:58 PM ET
5-Strong Sell of 5 5
F Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRDX 35.41 -0.22(-0.62%)
Will SRDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRDX
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
Are Options Traders Betting on a Big Move in Surmodics Stock?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
Other News for SRDX
Surmodics (SRDX) Stock Drops Amid FTC Deadline Extension Request
Surmodics falls as parties, FTC ask for extension of briefing schedule
Noteworthy Monday Option Activity: SRDX, CR, SPOT
Surmodics (SRDX) Shares Climb 12% Amid FTC Pre-Trial Hearing
Surmodics jumps amid pre-trial hearing in FTC's suit to block sale to GTCR